XML 49 R39.htm IDEA: XBRL DOCUMENT v3.19.2
Shareholders' Equity (Details) - USD ($)
1 Months Ended 6 Months Ended
Aug. 03, 2017
Oct. 25, 2018
Mar. 28, 2018
Sep. 30, 2016
Jun. 30, 2019
Jun. 30, 2018
Jan. 25, 2019
Dec. 31, 2018
Shareholders' Equity (Textual)                
Stock based compensation         $ 114,012 $ 1,203,903    
Recognized total expense           $ 22,500    
Gross proceeds from equity $ 7,000,000              
Common stock, shares issued         27,556,121     23,640,621
Stock Award Agreements [Member]                
Shareholders' Equity (Textual)                
Stock based compensation     $ 944,300          
Unamortized stock compensation         $ 41,667      
Expense         $ 62,500      
Strategic Advisory Board Amendments [Member]                
Shareholders' Equity (Textual)                
Warrant term 5 years              
Description of equity based compensation The SAB Amendments extend the term of the agreements from May 1, 2017 until April 30, 2018 and provide for the following equity based compensation: (a) for Dr. Frost, a warrant to purchase 2,000,000 shares of the Company’s Common Stock (the “Frost Warrant”) and an award of 150,000 shares of the Company’s unregistered restricted Common Stock and (b) for Mr. Rubin, an award of 100,000 shares of the Company’s unregistered restricted Common Stock. The restricted stock vests upon the occurrence of a change of control (as defined in the SAB Amendments). The Warrant has a term of five years and exercise price of $1.00 per share subject to proportional adjustment in the event of stock splits, stock dividends and similar corporate events. The Company recognized $22,500 expense for the pro rata portion of shares earned by the two members during the six months ended June 30, 2018, amortizing the expense over the 12 months of the service agreement regardless of the vesting condition. The SAB Amendments extend the term of the agreements from November 1, 2018 until October 31, 2019 and provide for the following equity-based compensation: (a) for Dr. Frost, an award of 150,000 shares of the Company’s unregistered restricted Common Stock and (b) for Mr. Rubin, an award of 100,000 shares of the Company’s unregistered restricted Common Stock. The restricted stock vests upon the occurrence of a change of control (as defined in the SAB Amendments). The Company recognized $62,500 expense for the pro rata portion of shares earned by the two members during the six months ended June 30, 2019, amortizing the expense over the 12 months of the service agreement regardless of the vesting condition. As of June 30, 2019, the Company had unamortized stock compensation of $41,667 related to these two stock awards.            
Stock Compensation Plan [Member]                
Shareholders' Equity (Textual)                
Aggregate shares of common stock       1,349,000        
Restricted common stock, description       The Company issued 1,349,000 shares of restricted common stock outside of the 2015 Equity Plan to Jay Nussbaum, Felicia Hess, Daniyel Erdberg, Kendall Carpenter, Mike Silverman and Reginald Brown pursuant to Stock Award Agreements. The shares will vest upon consummation of a significant equity and/or debt financing of at least $5,000,000 provided that the holder remains engaged by the Company through the vesting date. On August 3, 2017, these awards were modified so that the restrictions set forth in the RSA lapse upon the earlier of (i) consummation of a significant equity and/or debt financing from which the Company receives gross proceeds of at least $7,000,000 or (ii) a change in control (as defined in the RSA Amendment), provided that, in either case, the holder remains engaged by the Company through the date of such event.        
Shares vest upon consummation of equity and/or debt financing       $ 5,000,000        
Amended and Restated Stock Purchase Agreement [Member]                
Shareholders' Equity (Textual)                
Common stock, shares issued             3,915,500  
Common stock per price               $ 0.50
Cash and notes receivable               $ 1,957,750